nach oben

Comprehensive Therapy

Erschienen in:

01.06.2007 | Original Article

Submicrobial Doxycycline and Rosacea

verfasst von: Ronald D. Wise

Erschienen in: Comprehensive Therapy | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Rosacea is a disease of inflammation with no pathogenic bacteria involved. Successful treatment of rosacea is possible without using antimicrobial preparations. Oracea™ capsules provide the antiinflammatory benefits of doxycycline without contributing to the development of resistance to doxycycline.

Sande MA, Mandell GL. Antimicrobial agents. In: Gilman, AG, Rall, TW, Nies, AS, Taylor, P, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. McGraw-Hill; 1993. p.1117–25.

Meyers B, Salvatore M. Tetracyclines and chloramphenicol. In: Mandell Gl, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia, PA: Elsevier; 2005. p. 357–66.

Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: Mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992;5(4):38–99.

Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. SKINmed 2003;2(4):234–45, Review.PubMedCrossRef

Baldwin HE. Oral therapy for rosacea. J Drugs Dermatol 2006;5(1):16–21.PubMed

Levy SB. The challenge of antibiotic resistance. Sci Am 1998;278(3):46–53.PubMedCrossRef

Bernstein JM. Treatment of community-acquired pneumonia-IDSA guidelines. Chest 1999;1115:95–135.

Stanford Hospital & Clinics. Antibiotic susceptibility of bacteria and yeasts. Available at: http://med.stanford.edu/lane/schid/susceptibility/ReportB.htm. (Accessed February 10, 2006).

US Food and Drug Administration. FDA publishes final rule to require labeling about antibiotic resistance. FDA News. Available at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00869.html. (Accessed February 10, 2006).

Powell FC. Rosacea. N Engl J Med 2005;352(8):793–803.PubMedCrossRef

National Rosacea Society. 14 million Americans urged to face up to rosacea before it gets worse. News Releases. April; 1, 2005. Available at: http://www.rosacea.org/press/archive/20050401.html. (Accessed February 10, 2006).

Milliklin L. The proposed inflammatory pathophysiology of rosacea: Implications for treatment. SKINmed 2003;2(1):43–7.CrossRef

Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venerol 1989;69(5):419–23.PubMed

Wilkin J, Dahl M, Detmar M. et al. Standard classification of rosacea. Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2004;50(6):907–12.PubMedCrossRef

Crawford GH, Pelle MT, James, WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004;51(3):327–41.PubMedCrossRef

Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea. Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002;46(4):584–87.PubMedCrossRef

Jansen T, Plewig GJ. Rosacea: classification and treatment. R Soc Med 1997;90(3):144–50.

Buechner SA. Rosacea: An update. Dermatology 2005;201(2):100–8.CrossRef

Bikowski JB. What you should know about subantimicrobial dose doxycycline. Pract Dermatol 2005;2(6):38–43.

Jones D. Reactive oxygen species and rosacea. Cutis 2004;74(Suppl 3):17–20, Review.PubMed

Miyachi Y. Potential antioxidant mechanism of action for metronidazole: Implications for rosacea management. Adv Ther 2001;18(6):237–43.PubMed

Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966;78(12):649–52.PubMedCrossRef

Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54(2):258–65.PubMedCrossRef

Del Russo JQ. The antibiotic paradox: benefits and risks of using antimicrobial oral antibiotics for the systemic treatment of rosacea. Cutis 2004;74(2):118–22.

Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12(2):12–26.PubMedCrossRef

Schroeder K, Lee H, Wolff M, et al. Low-dose tetracyclines (TCs) decrease elastase and beta-glucuronidase activities in gingival crevicular fluid (GCF) [abstract 1090]. J Dent Res 1990;69(special issue):245.

Schroeder KL, Ramamurphy NS, Szczepanek KA, et al. Low–dose tetracycline prevents attachment loss in adult periodontitis [abstract 1936]. J Dent Res 1992;71:758.

Skidmore R, Kovach R, Walker C, et al. Effects of submicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003;39(4):459–64.CrossRef

Del Rosso JQ, Bikowski J. When is an antibiotic not an antibiotic? Skin & Aging. 2004;11:36–42.

Golub LM, Wolff M, Roberts S, et al. Treating periodontal diseases by blocking tissue-destructive enzymes. J Am Dent Assoc 1994;125:163–69 (discussion 169–71).PubMed

Oracea. Newtown, PA: CollaGenex Pharmaceuticals; 2006 (prescribing information).

Titel: Submicrobial Doxycycline and Rosacea
verfasst von: Ronald D. Wise
Publikationsdatum: 01.06.2007
Verlag: Humana Press Inc
Erschienen in: Comprehensive Therapy / Ausgabe 2/2007
Print ISSN: 0098-8243
Elektronische ISSN: 1559-1190
DOI: https://doi.org/10.1007/s12019-007-8003-x

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Conjunctival Pigmentation in Stevens–Johnson Syndrome

Hepatitis C: Epidemiology, Diagnosis, and Management

Risk Factors for Acute Retinopathy of Prematurity

Editorial

CME Questions

Disease-Specific Depression and Outcomes in Chronic Heart Failure: A Propensity Score Analysis